Jefferies Assumes Nektar Therapeutics (NKTR) at Hold

May 31, 2022 8:28 AM EDT
Get Alerts NKTR Hot Sheet
Price: $3.24 -1.22%

Rating Summary:
    12 Buy, 11 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 0
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Jefferies analyst Roger Song assumes coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Hold rating and a price target of $4.00 (from $12.00).

The analyst commented, "Nektar has reprioritized two lead immunology/oncology programs. NKTR-358,an IL-2 Treg activator, has generated promising clinical data in systemic lupus erythematosus (SLE) and atopic dermatitis (AD). NKTR is partnering with LLY to advance to Ph2s, with data in ’23/’24. NKTR-255, an IL-15 agonist, is in Ph1s for cancers, with data updates in 2H22. In this long-term value, we see a path to rebuilding confidence post-BEMPEG setback. Assume at Hold & $4 PT"

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $3.54 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co